We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.51% | 43.28 | 43.64 | 43.255 | 43.63 | 131,403 | 14:58:19 |
From May 2019 to May 2024
By Adriano Marchese
GlaxoSmithKline PLC (GSK.LN) said Wednesday that a study found high efficacy rates and no cases of treatment emergent resistance for its two HIV drugs, Dolutegravir and Lamivudine.
ViiV Healthcare, of which GlaxoSmithKline is a majority shareholder, said that week 96 data from the GEMINI studies demonstrate that the clinical benefits of Dolutegravir plus Lamivudine at week 48 are sustainable. It also said that the findings provide further evidence of the benefits of two-drug regimen.
"These latest findings are important for people living with HIV who will potentially spend decades taking medication to manage their HIV," Principal Investigator for the GEMINI study program, Pedro Cahn, said.
Write to Adriano Marchese at adriano.marchese@dowjones.com
(END) Dow Jones Newswires
July 24, 2019 11:47 ET (15:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
